Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK‐438 (vonoprazan), a novel potassium‐competitive acid blocker, in healthy male subjects
Alimentary Pharmacology & Therapeutics2015Vol. 41(7), pp. 636–648
Citations Over TimeTop 1% of 2015 papers
Helen Jenkins, Yuichi Sakurai, Akira Nishimura, Hiroyuki Okamoto, Mark G. Hibberd, Richard O. Jenkins, Tomoki Yoneyama, Kiyoshi Ashida, Yoichiro Ogama, Steve Warrington
Abstract
TAK-438 in multiple rising oral dose levels of 10-40 mg once daily for 7 days was safe and well tolerated in healthy men and caused rapid, profound and sustained suppression of gastric acid secretion throughout each 24-h dosing interval. Clinicaltrials.gov identifiers: NCT02123953 and NCT02141711.
Related Papers
- → Pharmacokinetics of etoposide with intravenous drug administration in children and adolescents(2003)22 cited
- Determination fudosteine in plasma and its pharmacokinetics by LC-MS(2008)
- Pharmacokinetics of Tinidazole Tablet in Muslim and Han Healthy Volunteers(2008)
- Study on Pharmacokinetics and Pharmacodynamics of Pazufloxacin Mesilate in Healthy Volunteers(2008)
- Pharmacokinetics study of lansoprazole for injection in Chinese healthy volunteers(2011)